LPL Financial LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

LPL Financial LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 274.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 367,878 shares of the company's stock after purchasing an additional 269,682 shares during the period. LPL Financial LLC owned approximately 0.10% of Moderna worth $15,296,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Cerity Partners LLC boosted its position in shares of Moderna by 7.0% during the 3rd quarter. Cerity Partners LLC now owns 13,769 shares of the company's stock worth $920,000 after purchasing an additional 900 shares during the period. Quantbot Technologies LP acquired a new position in Moderna during the third quarter worth $150,000. Townsquare Capital LLC boosted its position in shares of Moderna by 42.7% during the third quarter. Townsquare Capital LLC now owns 5,288 shares of the company's stock worth $353,000 after buying an additional 1,583 shares during the period. Public Sector Pension Investment Board grew its stake in shares of Moderna by 18.0% in the third quarter. Public Sector Pension Investment Board now owns 16,380 shares of the company's stock valued at $1,095,000 after buying an additional 2,500 shares in the last quarter. Finally, Benjamin Edwards Inc. grew its stake in shares of Moderna by 14,009.7% in the third quarter. Benjamin Edwards Inc. now owns 4,374 shares of the company's stock valued at $292,000 after buying an additional 4,343 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. UBS Group lowered their target price on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 15th. Finally, Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Moderna presently has an average rating of "Hold" and a consensus target price of $59.00.

Moderna Trading Down 2.4 %

Shares of Moderna stock traded down $0.62 during trading on Friday, reaching $25.11. The company's stock had a trading volume of 16,041,074 shares, compared to its average volume of 7,025,575. The firm has a market cap of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. The company has a 50-day moving average price of $33.55 and a two-hundred day moving average price of $43.01. Moderna, Inc. has a fifty-two week low of $23.76 and a fifty-two week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.